RT Journal Article
SR Electronic
T1 Brain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model
JF Clinical Cancer Research
JO Clin Cancer Res
FD American Association for Cancer Research
DO 10.1158/1078-0432.CCR-14-2681
A1 Bai, Ren-Yuan
A1 Staedtke, Verena
A1 Wanjiku, Teresia
A1 Rudek, Michelle A.
A1 Joshi, Avadhut
A1 Gallia, Gary L.
A1 Riggins, Gregory J.
YR 2015
UL http://clincancerres.aacrjournals.org/content/early/2015/06/03/1078-0432.CCR-14-2681.abstract
AB Purpose: Mebendazole (MBZ), first used as an antiparasitic drug, shows preclinical efficacy in models of glioblastoma and medulloblastoma. Three different mebendazole polymorphs (A, B, and C) exist, and a detailed assessment of the brain penetration, pharmacokinetics, and antitumor properties of each individual mebendazole polymorph is necessary to improve mebendazole-based brain cancer therapy.Experimental Design and Results: In this study, various marketed and custom-formulated mebendazole tablets were analyzed for their polymorph content by IR spectroscopy and subsequently tested in an orthotopic GL261 mouse glioma model for efficacy and tolerability. The pharmacokinetics and brain concentration of mebendazole polymorphs and two main metabolites were analyzed by LC/MS. We found that polymorph B and C both increased survival in a GL261 glioma model, as B exhibited greater toxicity. Polymorph A showed no benefit. Polymorph B and C both reached concentrations in the brain that exceeded the IC50 in GL261 cells 29-fold. In addition, polymorph C demonstrated an AUC0–24h brain-to-plasma (B/P) ratio of 0.82, whereas B showed higher plasma AUC and lower B/P ratio. In contrast, polymorph A presented markedly lower levels in the plasma and brain. Furthermore, the combination with elacridar was able to significantly improve the efficacy of polymorph C in GL261 glioma and D425 medulloblastoma models in mice.Conclusion: Among mebendazole polymorphs, C reaches therapeutically effective concentrations in the brain tissue and tumor with fewer side effects, and is the better choice for brain cancer therapy. Its efficacy can be further enhanced by combination with elacridar. Clin Cancer Res; 1–9. ©2015 AACR.